Further experience with the use of 6-thioguanine in patients with Crohn's disease

Inflammatory Bowel Diseases

Volumn 14, Issue 10, 2008, Pages 1399-1405

  Ansari, Azhar ^a   Elliott, Tim ^a   Fong, Farina ^a   Arenas Hernandez, Monica ^a   Rottenberg, Giles ^a   Portmann, Bernard ^b   Lucas, Sebastian ^a   Marinaki, Anthony ^a   Sanderson, Jeremy ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

6 Mercaptopurine; 6 Thioguanine; Azathioprine; Crohn's disease; IBD; Pharmacogenetics; Thiopurines

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TIOGUANINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERYTHROCYTE LEVEL; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HYPERPLASIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATITIS; PATIENT COMPLIANCE; PORTAL HYPERTENSION; PRIORITY JOURNAL; RASH; REMISSION; SIDE EFFECT; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; BIOPSY; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHILD; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; LIVER; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SAFETY; TIME;

ADOLESCENT; ADULT; BIOPSY; CHILD; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SAFETY; THIOGUANINE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 59749103590     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20492     Document Type: Article

References (29)

1. Pearson DC, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database System Rev. 2000: CD000067.
2. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-987.
3. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292-297.
4. Skelly MM, Logan RF, Jenkins D, et al. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:93-97.
5. Bean RHD. Treatment of ulcerative colitis with antimetabolites. Br Med J 1966:1081-1084.
6. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis. 2001;7:181-189.
7. Ferlitsch A, Teml A, Reinisch W, et al. 6-Thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol. 2007;102: 2495-2503.
8. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003;125:298-303.
9. de Boer NK, Reinisch W, Teml A, et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion. 2006;73:25-31.
10. Gilissen LP, Derijks LJ, Driessen A, et al. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig Liver Dis. 2007;39:156-159.
11. Rabel SR, Stobaugh JF, Trueworthy R. Determination of intracellular levels of 6-mercaptopurine metabolites in erythrocytes utilizing capillary electrophoresis with laser-induced fluorescence detection. Anal Biochem. 1995;224:315-322.
12. Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol. 2003;98:1058-1063.
13. Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;14:181-187.
14. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915.
15. McGovern DP, Travis SP, Duley J, et al. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology. 2002;122:838-839.
16. Lennard L, Hale JP, Lilleyman JS. Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br J Clin Pharmacol. 1993;36:277-284.
17. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology (Baltimore). 2006;44: 7-14.
18. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology (Baltimore). 1990;11:787-797.
19. Shastri S, Dubinsky MC, Fred Poordad F, et al. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch Pathol Lab Med. 2004;128:49-53.
20. Reiss U, Cowan M, McMillan A, et al. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol. 2002;24:746-750.
21. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001; 6:162-176.
22. de Boer NK, Mulder CJ, van Bodegraven AA. Nodular regenerative hyperplasia and thiopurines: the case for level-dependent toxicity. Liver Transpl. 2005;11:1300-1301.
23. De Bruyne R, Portmann B, Samyn M, et al. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J Hepatol. 2006;44:407-410.
24. Ravikumara M, Hill FG, Wilson DC, et al. 6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia - a dual-centre experience. J Pediatr Gastroenterol Nutrition. 2006;42:535-538.
25. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007;56:1404-1409.
26. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104:1574-1577.
27. Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monitor. 2005;27:647-654.
28. Shipkova M, Armstrong VW, Wieland E, et al. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin Chem. 2003;49:260-268.
29. Seiderer J, Zech CJ, Reinisch W, et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol. 2005;43:303-309.